OBJECTIVE: To determine the proportion of patients with atrial fibrillation (AF) in primary care achieving guideline-concordant stroke prevention treatment based on both the previous (2010) and the updated (2012) Canadian guideline recommendations. DESIGN: Retrospective chart review. PARTICIPANTS: Primary care patients (N = 204) with AF. The mean age was 71.3 years and 53.4% were women. SETTING: Large urban community family practice in Toronto, Ont. MAIN OUTCOME MEASURES: Patient demographic characteristics such as sex and age; a list of current cardiac medications including anticoagulants and antiplatelets; the total number of medications; relevant current and past medical history including presence of diabetes, stroke or transient ischemic attack, hypertension, and vascular disease; number of visits to the family physician and cardiologist in the past year and past 5 years, and how many of these were for AF; the number of visits to the emergency department or hospitalizations for AF, congestive heart failure, or stroke; if patients were taking warfarin, how often their international normalized ratios were recorded, and how many times they were in the reference range; CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and stroke or transient ischemic attack) score, if recorded; and reason for not taking oral anticoagulants when they should have been, if recorded. RESULTS: Among those who had CHADS2 scores of 0, 64 patients (97.0%) were receiving appropriate stroke prevention in AF (SPAF) treatment according to the 2010 guidelines. When the 2012 guidelines were applied, 39 patients (59.1%) were receiving appropriate SPAF treatment (P < .001). For those with CHADS2 scores of 1, 88.4% of patients had appropriate SPAF treatment according to the 2010 guidelines, but only 55.1% were adequately treated according to the 2012 guidelines (P < .001). Of the patients at the highest risk (CHADS2 score > 1), 68.1% were adequately treated with anticoagulation and an additional 8.7% (6 of 69) had documented reasons why they were not taking anticoagulants. CONCLUSION: When assessed using the 2012 Canadian Cardiovascular Society AF guidelines, the proportion of patients receiving appropriate SPAF therapy in this primary care setting decreased substantially. All patients with CHADS2 scores of 0 or 1 should be reassessed to ensure that they are receiving optimal stroke prevention treatment.
OBJECTIVE: To determine the proportion of patients with atrial fibrillation (AF) in primary care achieving guideline-concordant stroke prevention treatment based on both the previous (2010) and the updated (2012) Canadian guideline recommendations. DESIGN: Retrospective chart review. PARTICIPANTS: Primary care patients (N = 204) with AF. The mean age was 71.3 years and 53.4% were women. SETTING: Large urban community family practice in Toronto, Ont. MAIN OUTCOME MEASURES: Patient demographic characteristics such as sex and age; a list of current cardiac medications including anticoagulants and antiplatelets; the total number of medications; relevant current and past medical history including presence of diabetes, stroke or transient ischemic attack, hypertension, and vascular disease; number of visits to the family physician and cardiologist in the past year and past 5 years, and how many of these were for AF; the number of visits to the emergency department or hospitalizations for AF, congestive heart failure, or stroke; if patients were taking warfarin, how often their international normalized ratios were recorded, and how many times they were in the reference range; CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and stroke or transient ischemic attack) score, if recorded; and reason for not taking oral anticoagulants when they should have been, if recorded. RESULTS: Among those who had CHADS2 scores of 0, 64 patients (97.0%) were receiving appropriate stroke prevention in AF (SPAF) treatment according to the 2010 guidelines. When the 2012 guidelines were applied, 39 patients (59.1%) were receiving appropriate SPAF treatment (P < .001). For those with CHADS2 scores of 1, 88.4% of patients had appropriate SPAF treatment according to the 2010 guidelines, but only 55.1% were adequately treated according to the 2012 guidelines (P < .001). Of the patients at the highest risk (CHADS2 score > 1), 68.1% were adequately treated with anticoagulation and an additional 8.7% (6 of 69) had documented reasons why they were not taking anticoagulants. CONCLUSION: When assessed using the 2012 Canadian Cardiovascular Society AF guidelines, the proportion of patients receiving appropriate SPAF therapy in this primary care setting decreased substantially. All patients with CHADS2 scores of 0 or 1 should be reassessed to ensure that they are receiving optimal stroke prevention treatment.
Authors: Brian Hazelhurst; Mary Ann McBurnie; Richard A Mularski; Jon E Puro; Susan L Chauvie Journal: Am J Manag Care Date: 2012-06 Impact factor: 2.229
Authors: Adam Wright; Justine Pang; Joshua C Feblowitz; Francine L Maloney; Allison R Wilcox; Harley Z Ramelson; Louise I Schneider; David W Bates Journal: J Am Med Inform Assoc Date: 2011-05-25 Impact factor: 4.497
Authors: Allan C Skanes; Jeff S Healey; John A Cairns; Paul Dorian; Anne M Gillis; M Sean McMurtry; L Brent Mitchell; Atul Verma; Stanley Nattel Journal: Can J Cardiol Date: 2012 Mar-Apr Impact factor: 5.223
Authors: Vallerie V McLaughlin; Anatoly Langer; Mary Tan; Philip J Clements; Ronald J Oudiz; Victor F Tapson; Richard N Channick; Lewis J Rubin Journal: Chest Date: 2013-02-01 Impact factor: 9.410
Authors: Christopher Licskai; Todd Sands; Michael Ong; Lisa Paolatto; Ivan Nicoletti Journal: Int J Qual Health Care Date: 2012-08-14 Impact factor: 2.038
Authors: Theresa M Lee; Noah M Ivers; Sacha Bhatia; Debra A Butt; Paul Dorian; Liisa Jaakkimainen; Kori Leblanc; Dan Legge; Dante Morra; Alissia Valentinis; Laura Wing; Jacqueline Young; Karen Tu Journal: Implement Sci Date: 2016-12-03 Impact factor: 7.327